A Phase 2a Safety and Efficacy Open-Label Study of Tulisokibart (MK-7240/PRA023) in Participants With Moderately to Severely Active Crohn's Disease (MK-7240-006)
Public ClinicalTrials.gov record NCT05013905. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2a, Multi-Center, Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of PRA023 in Subjects With Moderately to Severely Active Crohn's Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the safety and efficacy of tulisokibart (MK-7240) in participants with moderately to severely active Crohn's Disease. After the completion of the 12-week Induction Period, eligible participants have the option to enter an Open-label Extension (OLE) Period for up to 170 weeks.
Study identification
- NCT ID
- NCT05013905
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Enrollment
- 55 participants
Conditions and interventions
Conditions
Interventions
- Tulisokibart Biological
- Companion Diagnostic (CDx) Diagnostic Test
Biological · Diagnostic Test
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 28, 2021 (Actual)
- Primary completion
- Sep 23, 2022 (Actual)
- Completion
- May 27, 2025 (Actual)
- Last update posted
- Jul 22, 2026
2021 – 2025
United States locations
- U.S. sites
- 16
- U.S. states
- 8
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Prometheus Biosciences Selected Site | Los Angeles | California | 90045 | — |
| Prometheus Biosciences Selected Site | Los Angeles | California | 90048 | — |
| Prometheus Biosciences Selected Site | Liberty | Kansas | 64098 | — |
| Prometheus Biosciences Selected Site | Chesterfield | Michigan | 48047 | — |
| Prometheus Biosciences Selected Site | Ypsilanti | Michigan | 48197 | — |
| Prometheus Biosciences Selected Site | St Louis | Missouri | 63141 | — |
| Prometheus Biosciences Selected Site | Lebanon | New Hampshire | 03756 | — |
| Prometheus Biosciences Selected Site | New York | New York | 10065 | — |
| Prometheus Biosciences Selected Site | Garland | Texas | 75044 | — |
| Prometheus Biosciences Selected Site | Lubbock | Texas | 79410 | — |
| Prometheus Biosciences Selected Site | Lubbock | Texas | 79424 | — |
| Prometheus Biosciences Selected Site | San Antonio | Texas | 78229 | — |
| Prometheus Biosciences Selected Site | Southlake | Texas | 78229 | — |
| Prometheus Biosciences Selected Site | Tyler | Texas | 75702 | — |
| Prometheus Biosciences Selected Site | Bellevue | Washington | 98004 | — |
| Prometheus Biosciences Selected Site | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05013905, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 22, 2026 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05013905 live on ClinicalTrials.gov.